Novartis prostate cancer drug trial meets primary endpoint By: MarketWatch December 05, 2022 at 01:44 AM EST The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said. Read More >> Related Stocks: Novartis AG Common Stock